Lipid-based amphotericin B formulations (ABCD/L-AmB) were associated with better outcomes than deoxycholate (AmB-d) in non-HIV-associated cryptococcal meningitis: A retrospective cohort study
Medical Mycology · 01.05.2026 · 64 (5)
DOI: 10.1093/mmy/myag033 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Medical Mycology, online erschienen am 16.04.2026. Verfasst von Junyu Liu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510630, PR China. Hauptthemen laut MEDLINE: Amphotericin B, Meningitis, Cryptococcal, Antifungal Agents, Deoxycholic Acid. Die Arbeit nennt 28 Literaturangaben. Gefördert von: Clinical High-tech, Characteristic Technology Projects in Guangzhou.
Abstract (Originalsprache)
This retrospective cohort study compared the efficacy and safety of lipid-based amphotericin B formulations (amphotericin B colloidal dispersion [ABCD] and liposomal amphotericin B [L-AmB]) versus conventional amphotericin B deoxycholate (AmB-d) for the treatment of non-human immunodeficiency virus (HIV)-associated cryptococcal meningitis (CM). Data from 199 patients were analyzed, divided into three groups based on induction therapy: AmB-d (n = 110), ABCD (n = 44), and L-AmB (n = 45). At baseline, a higher proportion of patients in the lipid-based groups presented with altered mental status. After 2 weeks, the ABCD and L-AmB groups showed significantly better clinical improvement (as measured by British Medical Research Council Stage 1) compared to the AmB-d group (63.6% and 77.8% vs. 35.5%; P < .001), and experienced substantially lower rates of renal impairment (54.5% and 53.3% vs. 79.1%; P = .001). Early fungicidal activity was similar across all groups. Multivariate analysis at 10 weeks indicated that both lipid-based formulations were associated with a lower risk of unsuccessful outcomes compared to AmB-d. Furthermore, 1-year survival analysis for clinical cure demonstrated a significantly higher cumulative incidence in the lipid-based AmB groups (Log-rank test, P = .016). In conclusion, induction regimens based on ABCD or L-AmB were associated with better outcomes than AmB-d for non-HIV-associated CM, offering better long-term outcomes and a more favorable safety profile, particularly regarding kidney toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510630, PR China.
ORCID-Profile: Junyu Liu
Förderung
- Clinical High-tech
- Characteristic Technology Projects in Guangzhou
Zitieren
APA
Liu, J., Liu, J., Li, M., Dong, R., Li, D., Chen, J., Zeng, W., Li, Z., Xu, X., Jiang, Y., & Peng, F. (2026). Lipid-based amphotericin B formulations (ABCD/L-AmB) were associated with better outcomes than deoxycholate (AmB-d) in non-HIV-associated cryptococcal meningitis: A retrospective cohort study. Medical Mycology, 64(5). https://doi.org/10.1093/mmy/myag033
Vancouver
Liu J, Liu J, Li M, Dong R, Li D, Chen J, et al. Lipid-based amphotericin B formulations (ABCD/L-AmB) were associated with better outcomes than deoxycholate (AmB-d) in non-HIV-associated cryptococcal meningitis: A retrospective cohort study. Medical Mycology. 2026;64(5). doi:10.1093/mmy/myag033
BibTeX
@article{Liu2026,
author = {Liu, Junyu and Liu, Jia and Li, Min and Dong, Ruiqi and Li, Dongcheng and Chen, Jiajie and Zeng, Wenhai and Li, Zheqi and Xu, Xiaofeng and Jiang, Ying and Peng, Fuhua},
title = {Lipid-based amphotericin B formulations (ABCD/L-AmB) were associated with better outcomes than deoxycholate (AmB-d) in non-HIV-associated cryptococcal meningitis: A retrospective cohort study},
journal = {Medical Mycology},
year = {2026},
volume = {64},
number = {5},
doi = {10.1093/mmy/myag033}
}
EUVIMED